Abstract: The present invention is directed to methods and compositions related to ?7 acetylcholine nicotinic receptor genes, in particular, the human ?7 nicotinic acetylcholine receptor gene. The human ?7 nicotinic acetylcholine receptor gene is associated with the pathophysiological aspects of the disease schizophrenia. The present invention further provides methods and compositions to screen populations for abnormal ?7 alleles, as well as methods and compositions for development of therapeutics.

Abstract: The present invention is directed to methods and compositions related to ?7 acetylcholine nicotinic receptor genes, in particular, the human ?7 nicotinic acetylcholine receptor gene. The human ?7 nicotinic acetylcholine receptor gene is associated with the pathophysiological aspects of the disease schizophrenia. The present invention further provides methods and compositions to screen populations for abnormal ?7 alleles, as well as methods and compositions for development of therapeutics.

Abstract: The present invention is directed to methods and compositions related to ?7 acetylcholine nicotinic receptor genes, in particular, the human ?7 nicotinic acetylcholine receptor gene. The human ?7 nicotinic acetylcholine receptor gene is associated with the pathophysiological aspects of the disease schizophrenia. The present invention further provides methods and compositions to screen populations for abnormal ?7 alleles, as well as methods and compositions for development of therapeutics.

Abstract: The invention relates to inhalation compositions derived from dehydroepiandrosterone sulfate. The compositions of the invention involve liquid nebulizer formulations prepared from dehydroepiandrosterone sulfate dihydrate. The compositions of the invention comprise water and chloride ion. The liquid nebulizer formulations can be used to treat patients suffering from asthma or COPD.

Abstract: This invention relates to a sealed container containing a powder formulation comprising a dehydroepiandrosterone, its analogue(s) or salt(s) by itself or with a pharmaceutically or veterinarily acceptable carrier or diluent, and having a particle size of about 0.1 ?m to about 100 ?m. The formulation can be used to treat or prevent asthma, chronic obstructive pulmonary disease, lung inflammation, and other respiratory diseases or conditions. The formulation may be prepared by jet milling, and may be delivered through the respiratory tract or other routes using a nebulizer. The sealed container is provided in a device and/or a therapeutic kit.

Abstract: The present invention is directed to methods and compositions related to ?7 acetylcholine nicotinic receptor genes, in particular, the human ?7 nicotinic acetylcholine receptor gene. This ?7 acetylcholine nicotinic receptor gene is associated with the pathophysiological aspects of the disease schizophrenia. The present invention further provides methods and compositions to screen populations for abnormal ?7, as well as methods and compositions for development of therapeutics.

Abstract: The present invention is directed to methods and compositions related to &agr;7 acetylcholine nicotinic receptor genes, in particular, the human &agr;7 nicotinic acetylcholine receptor gene. The human &agr;7 nicotinic acetylcholine receptor gene is associated with the pathophysiological aspects of the disease schizophrenia. The present invention further provides methods and compositions to screen populations for abnormal &agr;7 alleles, as well as methods and compositions for development of therapeutics.

Abstract: A formulation consisting essentially of an oligo(s) and bearing greater than about 90% particles about 0.1&mgr; to about 1&mgr;, or about 10&mgr; to about 50&mgr; in diameter. A dry powder formulation consisting essentially of an oligo of particle size about 0.1&mgr; to about 100&mgr; micron in diameter. Methods of preparation and therapeutic and diagnostic use are disclosed. Kits for diagnosis or treatment of numerous diseases and conditions by administration into the respiratory tract.

Abstract: This invention relates to a sealed container containing a powder formulation comprising a dehydroepiandrosterone, its analogue(s) or salt(s) by itself or with a pharmaceutically or veterinarily acceptable carrier or diluent, and having a particle size of about 0.1 &mgr;m to about 100 &mgr;m. The formulation can be used to treat or prevent asthma, chronic obstructive pulmonary disease, lung inflammation, and other respiratory diseases or conditions. The formulation may be prepared by jet milling, and may be delivered through the respiratory tract or other routes using a nebulizer. The sealed container is provided in a device and/or a therapeutic kit.